Axsome Therapeutics Inc

Axsome Therapeutics Inc. a biopharmaceutical company engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion) a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol) a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05 which is in Phase III clinical trial to treat Alzheimer's disease agitation as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07 an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12 an investigational medicine which is in Phase III trial to treat narcolepsy; AXS-14 a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol a dual-acting dopamine and norepinephrine reuptake inhibitor which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York New York.